Can you get semaglutide in the EU, and in what forms?

The short answer

Semaglutide is fully available in the EU — but only by prescription, under three EMA-approved brands: Wegovy (weight management), Ozempic (type 2 diabetes), and Rybelsus (the oral diabetes tablet). There is no legitimate "research" or over-the-counter route. The real barriers are eligibility, cost and reimbursement (which vary by country), and recurring supply shortages — not legality.

Evidence tier: 2 — based on documented EMA marketing authorizations and the established efficacy trials. Access/cost/supply observations are practical and vary by member state. This is education, not medical or legal advice.

The key points:

• Three EMA-approved brands — Wegovy (weight), Ozempic (diabetes), Rybelsus (oral)
• Prescription only — no legitimate OTC or "research" route in the EU
• The oral option exists — Rybelsus, unique among GLP-1s
• Barriers are cost, eligibility, and shortages — not legality

This is part of our EU availability cluster — see the EU peptide availability overview and the full semaglutide deep dive.

Is semaglutide legal and available in the EU?

Evidence tier: 1–2 — EMA marketing authorizations.

Yes — semaglutide is one of the most firmly established medicines in the EU, authorized centrally by the European Medicines Agency, so a single approval applies across all member states. It comes in three guises. Wegovy (the higher-dose weekly injection) received EU marketing authorization for weight management in January 2022 (EMA: Wegovy). Ozempic is the weekly injection authorized for type 2 diabetes. Rybelsus is the once-daily oral tablet, also for type 2 diabetes — notable because it's the only oral GLP-1 on the market.

All three are prescription-only medicines (POM). That status is the whole story for access: there is no legal over-the-counter or "research-use" channel for semaglutide in the EU, and the gray-market routes used for unapproved research peptides are both unnecessary and ill-advised for a drug that's properly available through a prescriber. So unlike, say, BPC-157 — covered in the EU availability overview — the question for semaglutide isn't "is there a legal route" but "do I qualify, and can I get it filled."

Injectable vs oral: which forms can you get?

Evidence tier: 2 — based on the approved formulations.

Both injectable and oral semaglutide are available in the EU, which makes it the most format-flexible GLP-1 here. The injectables (Wegovy, Ozempic) are once-weekly subcutaneous pens — the form with the strongest weight-loss data, around 15% average in the STEP program (Wilding 2021). The oral form (Rybelsus) is a daily tablet for diabetes; it's a genuine convenience for people who prefer not to inject, but it comes with specific administration rules (empty stomach, small sip of water, wait before eating) because oral peptide absorption is poor, and its weight effect is somewhat lower than the injectable.

A practical EU nuance: which brand you can actually obtain often depends on your indication. Weight-management access (Wegovy) is frequently private-pay and more tightly gated than diabetes access (Ozempic, Rybelsus), and during shortages prescribers have sometimes had to switch patients between products. The formulation choice, in other words, is partly a clinical decision and partly a question of what's in stock and what's reimbursed where you live. For the mechanism and full side-effect picture, see the semaglutide deep dive and our GLP-1 complete guide.

One point of confusion worth clearing up: Ozempic and Wegovy are the same molecule (semaglutide) at different dose ranges and with different approved indications, not different drugs. That's why, during Wegovy shortages, some patients and prescribers looked to Ozempic — but using a diabetes-branded product for weight loss is off-label, dose ranges differ, and it diverts supply from diabetes patients who need it, which regulators have discouraged. The clean takeaway is to match the brand to the indication: Wegovy for weight management, Ozempic for diabetes, Rybelsus if an oral diabetes option suits — and to treat brand-switching as a prescriber's call during supply disruptions rather than a DIY workaround.

What actually makes it hard to get?

Evidence tier: 2–3 — access-system observation, varies by country.

If semaglutide is legal and available, why do EU patients describe it as hard to get? Three reasons, none of them legality. First, eligibility: weight-management prescriptions typically require meeting BMI or comorbidity criteria, and many systems gate Wegovy more tightly than the diabetes brands. Second, cost and reimbursement: in several member states the weight-management indication is largely private-pay, so the barrier is financial rather than regulatory, and reimbursement rules differ markedly country to country. Third, shortages: surging demand has produced EU-wide supply constraints, and the EMA has had to coordinate actions to manage them (EMA on GLP-1 shortages) — so even an eligible, prescribed patient can find pharmacies out of stock or limited to certain pen strengths.

There's also a structural contrast with the US that shapes perception: the US grew a large telehealth-and-compounding ecosystem around GLP-1 demand, creating frictionless (if variable-quality) access, whereas the EU has tighter compounding rules and little equivalent. So the EU experience is "the real drug exists and is safe and regulated, but getting a script filled affordably can be a process" — the opposite of the gray-market research-peptide problem, where the drug is easy to buy but impossible to trust.

How does EU access compare to the US and UK?

Evidence tier: 2–3 — cross-market access observation.

The EU sits in an interesting middle position. In the US, semaglutide demand spawned a huge telehealth-and-compounding ecosystem: online consults, compounded "semaglutide" from outsourcing pharmacies, and aggressive direct-to-consumer marketing made access fast but quality-variable, and that compounding lane has since been tightened by the FDA. The EU never built that pipeline — compounding rules are stricter, cross-border prescribing is constrained, and there's no large legal compounding market — so EU access is more "traditional": a prescriber, an approved branded product, a pharmacy. That's slower and more gated, but it means what you get is the genuine, quality-controlled drug rather than a compounded approximation.

The UK (post-Brexit, regulated by the MHRA rather than the EMA) runs a broadly similar prescription model, with Wegovy access channelled through specialist services and private clinics and the same shortage pressures. The practical lesson for an EU resident is that the "easy US access" they read about online largely refers to the compounding route that doesn't legally exist in the same form in the EU — so importing or replicating it isn't a shortcut, it's a step into the gray market. The EU trade-off is real but defensible: less convenience, more certainty about what's in the pen. Where access is genuinely blocked by cost rather than rules, that's a reimbursement conversation, and it's improving as more countries assess the weight-management indication.

Should you ever buy semaglutide outside a pharmacy in the EU?

Evidence tier: 2–3 — risk reasoning; not legal advice.

The short answer is no. Because semaglutide is legitimately available by prescription, the gray-market "research" semaglutide sometimes sold online offers no advantage and substantial risk: it's unapproved, unregulated for quality, potentially counterfeit or mis-dosed, and buying injectable products of unknown origin carries the contamination concerns covered in our independent lab-testing guide. Compounded semaglutide — a major theme in the US — is far more constrained in the EU, and self-sourcing the raw drug is not a safe substitute for a prescription.

If cost or eligibility is the barrier, the constructive routes are a conversation with a GP or a specialist weight-management or diabetes service about whether you qualify and what's reimbursed, rather than the gray market. The honest framing for EU readers is that semaglutide is the good scenario among peptides — a real, regulated, well-evidenced medicine you can get properly — and the effort is worth it precisely because the alternative (an unverified vial of unknown content) trades a solvable access problem for an unsolvable safety one.

A note on cross-border purchasing within the EU: because semaglutide is approved EU-wide, the medicine is the same product across member states, but prescriptions, reimbursement, and pricing are national, so you generally can't sidestep your own country's eligibility or cost rules simply by ordering from another. Legitimate cross-border options (such as filling a valid prescription at a registered pharmacy in another member state) operate within EU pharmacy law, not around it — which is a different thing entirely from buying unbranded "semaglutide" from an unregulated website. When in doubt, the test is simple: a real semaglutide transaction involves a prescription and a registered pharmacy at some point; anything that skips both is the gray market.

Limitations

This is educational content, not medical or legal advice.

• Rules, reimbursement, and eligibility vary by EU member state — this is a general overview.
• Approval status and indications change — verify current EMA status and your local rules.
• Supply fluctuates — approved brands can be hard to fill during shortages.
• Gray-market semaglutide is unapproved and unsafe — a prescription is the only sound route.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Semaglutide is fully and legally available across the EU — but only by prescription, as Wegovy (weight), Ozempic (diabetes), or the oral Rybelsus tablet. There's no legitimate OTC or research route, and none is needed. The genuine obstacles are eligibility criteria, cost and patchy reimbursement (especially for weight management), and recurring shortages — access-system frictions, not legal ones. Unlike unapproved research peptides, this is the scenario where the right move is clearly a prescriber, not the gray market.

Related on this site

• EU peptide availability: the overview
• Semaglutide deep dive (2026)
• Tirzepatide in the EU (Mounjaro)
• Retatrutide in the EU: pipeline status
• GLP-1 complete guide (2026)
• Semaglutide peptide page
• Our evidence-tier framework

References

• European Medicines Agency. Wegovy (semaglutide) — EPAR / medicine overview. EMA: Wegovy — EU authorization for weight management (Jan 2022).
• European Medicines Agency. EU actions to tackle shortages of GLP-1 receptor agonists. EMA news — supply/access context.
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — injectable efficacy.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 389(24):2221-2232. PMID 37952131 — outcome evidence underpinning approval.